patients died. Sixteen (14.7%) patients expressed the MATE1 A/A variant. Median disease specific survival was 46.2 months in the MATE1 A/A patients and not reached in the G/G and G/A patients (hazard ratio 0.66 [95% confidence interval, 0.23 to 1.82]; PZ.42). Median overall survival was 55.27 months in the MATE1 A/A patients but also not reached G/G and G/A patients (hazard ratio 1.22 [95% confidence interval, 0.46 to 3.27]; PZ.17). Conclusion: Presence of the MATE1 A/A polymorphism did not compromise treatment efficacy in HNSCC patients receiving cisplatinbased chemoradiation. A small sample size and short duration of follow-up are limitations of our data. The MATE1 A/A polymorphism is associated with reduced ototoxicity risk from cisplatin without reduced anticancer activity and warrants further investigation in the treatment of HNSCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.